2024 年全球视网膜药物市场：地图样萎缩及其他非渗出性视网膜疾病

本报告研究了全球视网膜药物市场，概述了非渗出性视网膜疾病，并预测了市场成长的五年情况、未来的主要趋势以及市场竞争对手的概况。

目录

• 关于非渗出性视网膜疾病及其危险因子的思考
• 这些疾病的诊断和治疗
• 视网膜医学与视网膜专家的观点
• 已上市治疗非渗出性视网膜疾病的药物和生物製剂
• 正在研发中的试验性药物
• 开发和销售非渗出性视网膜疾病药物的公司简介，以及其他拥有临床前项目的公司列表

What's New:

This first-edition "2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases" estimates the prevalence of nonexudative retinal diseases and forecasts the treatment market by region for complement inhibitors, gene therapies, and more.

The report examines clinical-stage drug-development programs, reviews the development stages of drug- delivery platforms, and analyzes trends in doctor interest in complement inhibitors in both the United States and Western Europe, as well as patient dosing with complement inhibitors in the United States.

The "2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases" analyzes the market for complement inhibitors, gene therapies, antioxidants, sustained-release devices, and other treatments for geographic atrophy, dry AMD, and additional nonexudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines disease prevalence, reviews patient economics and reimbursement, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 19 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

This report explores a variety of topics intended to provide depth and context to the reader's understanding of market dynamics in this ophthalmic pharmaceutical segment. Our coverage includes:

• Discussions of nonexudative retinal diseases and their risk factors.
• Diagnosis and treatment of these diseases.
• A global view of retinal care and retina specialists.
• Pharmaceuticals and biologics in the marketplace for nonexudative retinal disease.
• Investigational agents in the development pipeline.
• Profiles of companies developing and marketing nonexudative retinal disease pharmaceuticals, plus a listing of additional companies with preclinical programs